Texas A&M University College of Medicine
PhD, Department of Medical Pharmacology
Harvard Medical School
Postdoctoral Fellow, Schepens Eye Research Institute
University of Texas Southwestern Medical Center at Dallas
Postdoctoral Fellow, Departments of Ophthalmology and Immunology
Major Contributions to Science
The Center for Therapeutic Development at BIIR is committed to developing novel therapies and biomarkers for cancer, infectious disease and autoimmune disease, discovered at BIIR. Our most advanced therapies are dendritic cell targeting vaccines for treatment of HIV injection, HPV-related cancers, and multiple sclerosis. Working with numerous other groups at BIIR and BRI, I am leading the efforts to bring these vaccines through preclinical development and into critical Phase 1 clinical trials at Baylor Scott & White.
Prior to joining BIIR, I was a principal scientist at Alcon Laboratories, a division of Novartis, from 2005 to 2012, where I headed a laboratory focused on drug discovery for allergic and inflammatory conditions of the eye. I also was a project team leader of early stage discovery efforts, bringing several new therapies into the development stage for proof-of-concept clinical trials.
My graduate and postdoctoral work examined the role of inflammation in dry eye disease and corneal transplant rejection. One of my major contributions was the identification of a new pathway of Th2 cell-mediated corneal allograft rejection in a mouse model in which the transplant recipients had allergic conjunctivitis. This finding was paradoxical to conventional wisdom that immune allograft rejection was due solely a Th1-mediated response and that a Th2 response would be tolerogenic.
Publications (out of 11 total from 2001 to 2012)
- Govek SP, Oshiro G, Anzola JV, Beauregard C, et al. Water-soluble PDE4 inhibitors for the treatment of dry eye.Bioorg Med Chem Lett, 2010; 20:2928-2932.
- Beauregard C, Stephens D, Roberts L, Gamache D, Yanni J. Duration of action of topical anti-allergy drugs in a guinea pig model of histamine-induced conjunctival vascular permeability.J Ocular Pharmacol Ther, 2007; 23:315-320.
- Beauregard C, Huq SO, Barabino S, Zhang Q, Kazlauskas A, Dana MR. Keratocyte apoptosis and failure of corneal allografts. Transplantation, 2006; 81:1577-1582.
- Stern ME, Siemasko KA, Gao J, Duong A, Beauregard C, Calder VL, Niederkorn JY. Role of interferon-γ in a mouse model of allergic conjunctivitis. Invest Ophthalmol Vis Sci, 2005; 46:3239-3246.
- Beauregard C, Stevens CS, Mayhew E, Niederkorn JY. Cutting edge: atopy promotes Th2 responses to alloantigens and increases the incidence and tempo of corneal allograft rejection. J Immunol, 2005; 174:6577-6581.
- Hegde S, Beauregard C, Mayhew ES, Niederkorn JY. CD4+ T cell-mediated mechanisms of corneal allograft rejection: role of Fas-induced apoptosis. Transplantation 2005; 79:23-31.
- Beauregard C, Brandt PC. Down regulation of interleukin-1-beta-induced nitric oxide production in lacrimal gland acinar cells by sex steroids. Curr Eye Res 2004; 29:59-66.
- Beauregard C, Brandt PC. Peroxisome proliferator-activated receptor agonists inhibit interleukin-1-beta-medaited nitric oxide production in cultured lacrimal gland acinar cells. J Ocular Pharmacol Ther 2003; 19:579-587.
- Beauregard C, Brandt PC, Chiou GCY. Induction of nitric oxide synthase and over-production of nitric oxide by interleukin-1beta in cultured lacrimal gland acinar cells. Exp Eye Res 2003; 77:109-114.
- Beauregard C, Brandt PC, Chiou GCY. Nitric oxide and cyclic GMP-stimulated protein secretion from cultured lacrimal gland acinar cells.J Ocular Pharmacol Ther 2002; 18:429-444.
- Beauregard C, Liu Q, Chiou GCY. Effects of nitric oxide donors and nitric oxide synthasesubstrates on isolated ciliary muscle contracted with carbachol or endothelin: possible use in myopia prevention. J Ocular Pharmacol Ther 2001; 17:1-10.